forbes article, page-7

It is biased and like pap says not a good look before this major contract.

As it is Forbes, I think this is going to have a negative impact on the SP.

At least with his article, it was critical but seemed like he had done his research though IMO he could have given AS some credit for signing with Sanofi. Surely they would have done their due diligence. I wonder who Abram spoke to at Sanofi? Was it the correct person who would deal with these type of deals? I guess Unilife would not be a top priority for Sanofi unless like AS says the deal is as large as we are led to believe?

I don't agree with Abram's comment about 13 years being an eternity in biotech, that is not correct IMO, it can and does take that long, some never get there or just fall short.

Jonny, you don't post much but when you do, to the point and sometimes very funny (no offence dino :)

It is funny now that the SP is up, dino's posts are thumbed down whereas not long ago they would be the top rated posts.

Interesting.